Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Biogen and Eisai reported a 54% jump in fourth‑quarter sales of their Alzheimer’s drug Leqembi, reaching $134 million, with $78 million generated in the United States. The increase follows the FDA’s approval of a once‑weekly subcutaneous injection, offering a less‑burdensome alternative to infusions during maintenance therapy. Biogen’s overall Q4 revenue fell 7% to $2.28 billion, but growth from Leqembi, Skyclarys, Zurzuvae and Qalsody helped offset declines in its multiple‑sclerosis and SMA franchises. An FDA decision on expanding the injectable to the induction phase is expected in early May.
1/ Bioinformatics takes years to master. Not because it’s hard. But because so much of what matters… no one writes down. Let me explain https://t.co/EEboWOxB5C
A new study by Sudbrack and Mullon shows that partial self‑fertilisation dramatically reshapes the evolution of tandem repeat (TR) sequences. Selfing increases homozygosity, amplifying variance from unequal recombination and strengthening selection across four regimes, resulting in lower genetic load despite...
University of Maryland researchers confirmed elevated concentrations of E. coli and several other pathogenic bacteria in the Potomac River after a recent sewage overflow. The study, conducted within weeks of the incident, found contaminant levels far above EPA recreational water...
University of Houston researchers led by Elena Grigorenko synthesized four decades of genetic data, analyzing 175 candidate genes linked to dyslexia. Their systematic review, published in the Journal of Speech, Language, and Hearing Research, reveals that reading difficulties stem from...
Fujifilm Biotechnologies, a subsidiary of the historic photo‑film maker, opened a 150‑acre, commercial‑scale biopharma manufacturing campus in Holly Springs, North Carolina, investing over $3.2 billion. The first phase features eight 20,000‑liter mammalian cell‑culture bioreactors, with a second phase slated to double...
January 2026 saw a slowdown in headline biopharma M&A, yet the deals that closed were strategically sizable. Amgen bought Dark Blue Therapeutics for $840 million, adding an AML protein‑degrader, while GSK acquired RAPT Therapeutics for $2.2 billion to expand its anti‑IgE portfolio....
Scientists have identified the phycosphere surrounding microalgae as a hidden hotspot for antibiotic resistance genes (ARGs) in freshwater systems. Organic exudates from algae attract bacteria that exchange ARGs through heightened horizontal gene transfer within dense biofilms. Nutrient runoff and algal...
Christos Papadelis has been appointed founding director of the Pediatric Brain Health and Neurosciences Center at the University of Texas at Arlington. The R1‑designated center will unite neurologists, bioengineers, data scientists and child‑health experts to accelerate translational research. Papadelis’s team...
UChicago Medicine has deployed a new intra‑operative magnetic resonance imaging (iMRI) suite that integrates real‑time imaging with neurosurgical navigation. The system shortens brain tumor resections by up to 30%, reduces postoperative complications by 20%, and allows surgeons to verify complete...
A new Lancet meta‑analysis of 23 randomized statin trials involving over 150,000 participants finds that most side effects listed on statin package leaflets are not caused by the drugs. The study reports no statistically significant increase in cognitive impairment, depression,...
An experimental surgical technique that temporarily removes the uterus, ovaries and fallopian tubes during colorectal cancer treatment has enabled a fifth baby, Lucien, to be born in Europe, marking the first successful post‑treatment birth on the continent. The same newsletter...
Strategic outsourcing is reshaping biopharma by linking discovery, formulation, and early‑clinical manufacturing through specialized external partners. In a Drug Digest interview, iOrganBio CEO Daniel Delubac explains how risk‑focused partner selection and integrated data flows accelerate cell, gene, and RNA therapies...
Ginkgo Bioworks, in partnership with OpenAI, deployed a GPT‑5‑driven autonomous lab that designed, executed, and learned from 36,000 cell‑free protein synthesis experiments. Over six iterative cycles, the system cut reaction component costs by 40%, achieving $422 per gram of superfolder...
Researchers demonstrated that polystyrene nanoplastics (PS‑NPs) are internalized by gonadotropin‑releasing hormone (GnRH) neurons and disrupt their function. In hormone‑secreting GT1‑7 cells, PS‑NP exposure lowered GnRH release, while in migrating GN11 progenitors it impaired cell movement. Transcriptomic profiling identified altered expression...
Researchers discovered that graphene oxide (GO) nanosheets act as direct photosensitizers for photodynamic therapy (PDT) when their lateral size exceeds ~3.5 µm. Under near‑infrared (NIR) irradiation, large GO generates abundant reactive oxygen species (ROS), driving oral squamous cell carcinoma viability down...
Former Generation Bio CEO Geoff McDonough has joined biotech NodThera to accelerate its NLRP3 inflammasome program, targeting a Phase 3 trial launch next year. The move underscores NodThera’s ambition to capture a fast‑growing market for anti‑inflammatory therapies. In parallel, Daiichi...
Priovant Therapeutics, a Roivant spin‑out, announced that brepocitinib – an experimental immune modulator inherited from Pfizer – achieved its primary efficacy endpoint in a Phase 2 trial for cutaneous sarcoidosis. The study demonstrated statistically significant reductions in skin lesion severity and...
Post‑Hoc Live hosted a deep‑dive into the emerging rivalry between Novo Nordisk and Hims & Hers over GLP‑1 therapies. Novo, the long‑time market leader with drugs like Ozempic and Wegovy, faces a new challenger as Hims rolls out a lower‑priced...
Roivant and its spin‑out Priovant reported that brepocitinib dramatically outperformed placebo in a 31‑patient trial for cutaneous sarcoidosis. Patients receiving the high‑dose regimen improved by an average of 22.3 points on a 165‑point disease activity scale, versus just 0.7 points...
Researchers engineered a mutant Hedgehog C‑terminal domain to covalently attach five distinct sterols to elastin‑like polypeptides, creating Sterol‑Modified Polypeptides (STaMPs). The sterol’s hydrophobicity (logD) dictates whether the resulting polymer remains monomeric or self‑assembles into spherical micelles. Sterol conjugation also shifts...
A recent review highlights nanomedicine approaches that target and reprogram macrophages to treat autoimmune diseases. By exploiting nanodrug platforms, researchers can deliver agents directly to pathogenic macrophages, minimizing systemic exposure. The strategy has shown efficacy across rheumatoid arthritis, inflammatory bowel...
Researchers at North Carolina State University have introduced a hybrid quantum‑classical framework that predicts electronic circular dichroism (ECD) spectra of chiral molecules using 20–24 qubit circuits. The method combines variational quantum eigensolvers with quantum equation‑of‑motion techniques and matches the accuracy...
Researchers have identified the ubiquitin ligase CUL5 as a negative regulator of tau protein levels in human neurons. A genome‑wide CRISPR interference screen in iPSC‑derived neurons highlighted CUL5 knockdown as a potent means to lower intracellular tau, echoing similar hits...
Researchers have identified muscularis macrophages (ME‑Macs) as pivotal carriers of misfolded α‑synuclein in the gut, facilitating its spread to the brain in Parkinson's disease models. Experimental depletion of ME‑Macs markedly reduced α‑synuclein pathology in both the enteric and central nervous...
Interesting difference: the corresponding US approval has no restriction to dMMR (remember PFS HR=0.60 in pMMR, but 0.30 in dMMR) $MRK
An experimental surgery that temporarily relocates the uterus, ovaries, and fallopian tubes during pelvic radiation allows cancer patients to preserve fertility. The technique, pioneered by Dr. Reitan Ribeiro and adopted by surgeons like Dr. Daniela Huber, has resulted in at...
Illumina announced a strategic pivot toward healthcare customers after the Trump administration’s disruptions to NIH funding slashed research‑sector spending. The company will expand its clinical‑grade sequencing platforms, accelerate partnerships with diagnostic labs, and pursue new reimbursement pathways. Illumina projects its...
Recent Phase I and II trials demonstrate that oral fecal microbiota transplantation (FMT) capsules can both mitigate immunotherapy‑induced toxicity in kidney cancer and markedly boost response rates in lung cancer and melanoma. In the kidney‑cancer study, 20 patients experienced fewer...
Eli Lilly’s ExploR&D program redefines pharma‑biotech partnerships by offering early‑stage companies shared‑risk, full‑stack R&D support. The model integrates Lilly’s discovery, chemistry, and clinical teams to accelerate the journey from molecule creation to proof‑of‑concept, especially in a tightening funding environment. It focuses...
The review surveys carbon‑nanotube (CNT) artificial muscles, detailing their structural designs—from flat sheets to coiled yarns and core‑sheath hybrids—and the range of multistimuli actuation mechanisms they support. It contrasts voltage‑driven electrochemical actuation with thermal, photothermal, and solvent‑induced pathways, highlighting performance...
Researchers have engineered a hierarchically assembled supramolecular nanomicelle with a gallium(III) core that integrates a metal–organic dye (Cy71‑Ga) and a camptothecin‑hyaluronate conjugate (CPT‑HA). The nanomicelle delivers targeted chemotherapy, photothermal/photodynamic therapy, and induces ferroptosis by downregulating xCT and CD98, while also...
Researchers have developed printable ion‑selective electrodes (ISEs) that replace traditional polyelectrolyte layers with Ti₃C₂Tx MXene nanoflakes on carbon fiber substrates. Two formats were demonstrated: MXene‑only electrodes on glass and screen‑printed MXene ISEs on flexible PVC, both targeting calcium‑ion detection. Tests...
Researchers introduced Nano‑Cell Vesicle Technology (nCVTs), a hybrid system that merges cationic lipids with tumor‑derived cell membranes to ferry antisense oligonucleotides (ASOs) into cancer cells. The platform achieved superior cytoplasmic and nuclear delivery compared with conventional liposomes and free ASOs,...
Mechanical threshold‑guided harvesting enables controlled production of designer nanovesicles from microalgae while preserving native carotenoid profiles and boosting antioxidant capacity. The study links vesiculation efficiency to cellular elasticity, identifying critical thresholds of roughly 100 kPa (local) and 390 kPa (global) membrane rigidity....
Researchers have engineered PEGylated PLGA nanoparticles encapsulating oxytocin for intranasal administration, aiming to improve nose‑to‑brain delivery for autism and related neuropsychiatric conditions. Using a design‑of‑experiments approach, the optimized formulation achieved ~93–116 nm particle size, low polydispersity, and drug loading of 2.8–3.5 %...
Researchers have identified a specific arginine‑tyrosine interaction that acts as a molecular “sticker” during spider silk formation, explaining how the fiber achieves its legendary strength and elasticity. Using AlphaFold3 modeling, molecular dynamics and NMR spectroscopy, the team showed these interactions...
The episode highlights Proscia’s recent achievements, including being named the Global 2026 Best in KLAS for Digital Pathology in Europe and a series of product and partnership milestones such as new AI tools for skin biomarkers, virtual staining, and integration...
Latent Labs, founded by former DeepMind researchers, has unveiled AI platforms that design drug‑like biologics in a single step. Leveraging generative foundation models inspired by AlphaFold2, the London‑based startup creates de novo macrocycles and antibodies for hard‑to‑drug targets. By addressing immunogenicity...
Steve Paul, a veteran CNS drug developer, argues that engineering breakthroughs—particularly in delivery, selectivity and tolerability—are turning long‑standing psychiatric hypotheses into viable medicines. He notes that psychiatry’s low success rates stem from polygenic disease biology and noisy trials, making human...
Researchers at Scripps Research and MIT engineered a DNA origami scaffold that carries HIV envelope proteins while remaining immunologically silent, eliminating antibodies against the carrier. In mouse models the DNA‑based particles displayed 60 copies of the antigen and generated ten...
Novo Nordisk spent billions developing GLP-1s. HIMS spent… a legal memo. Undercutting patented drugs while ignoring IP protections isn’t disruption... it’s erosion of the system that funds medical breakthroughs. 🔗 https://t.co/s63Kx8jBMf
Infleqtion, together with the University of Chicago and MIT, has entered Phase 3 of the Wellcome Leap Q4Bio Challenge, securing $2 million for a 12‑month validation of quantum‑enabled biomarker discovery. The effort focuses on using the hybrid HRQAOA algorithm to select predictive...
Researchers created a mouse model that overexpresses the cytoplasmic UBE3A isoform mIso2 and demonstrated that this manipulation fully rescues most Angelman syndrome (AS) behavioral deficits, including motor coordination, anxiety‑like behavior, and weight gain. However, the same overexpression does not correct...
A pilot randomized controlled trial tested a network analysis‑driven personalized digital intervention against a standard digital program for adults with depression. Using person‑specific symptom networks, the experimental arm delivered tailored content, while the control received a generic module. Over eight...
China’s neuropsychiatric drug landscape is accelerating, driven by regulatory reforms, increased NMPA approvals, and a surge in biotech investment. In 2023 the number of CNS‑focused new drug applications grew by roughly 30%, with several first‑in‑class agents entering late‑stage trials. Emerging...
FDA Commissioner Marty Makary publicly warned Hims & Hers that the agency will act quickly against its plan to compound Wegovy, the popular semaglutide weight‑loss injection. The warning follows reports that the telehealth firm intends to sell a lower‑cost, compounded...
FDA is stepping up within a matter of a few hours on the newest $HIMS oral semaglutide scam. This is a COMPLETE reversal of how the FDA has previously been (insanely) lenient with the mass compounding “personalization” scam that...
Angitia Biopharmaceuticals raised a $130 million Series D round, marking its second nine‑digit financing in just over a year after a $120 million Series C and following multiple nine‑figure Series B raises. New investors Frazier Life Sciences and Venrock Healthcare Capital Partners joined existing backers,...
Researchers at Arizona State University and international partners have unveiled a microfluidic droplet injector that reduces protein sample consumption in X‑ray free‑electron laser (XFEL) experiments by up to 97% while preserving data quality. The device delivers crystal‑laden droplets timed precisely...
